For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Zolpidem - Independent medicine & health information for consumers & professionals Zolpidem medicine information
Latest independent drug information about the active ingredient zolpidem and treatments, written and reviewed by experts in Australia.
Zolpidem is the active ingredient in the following brands of medicine:
- Dormizol
- Somidem
- Stildem
- Stilnox
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
| Zolpidem and sleep-related behaviours | NPS has published a position statement on the zolpidem safety change and to describe its place in insomnia therapy. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2008-08-01 00:00:00 |
| Benzodiazepines and non-drug treatments for insomnia | Covers benzodiazepine prescribing and the treatment of insomia. Compares non-drug treatments and herbal alternatives | Professional publication - NPS News | Health Professionals | 2002-10-01 00:00:00 |
| Evaluation of prescription drugs in Australia | A synopsis of the evaluation, dosage management and regulation of drugs in Australia, along with issues surrounding approaches to new drugs | Professional publication - NPS News | Health Professionals | 2001-12-01 00:00:00 |
| Warning to consumers about recreational use of medicines | The National Prescribing Service (NPS) warns people are playing Russian roulette with their health when they take medicines inappropriately. | Media release | Others | 2009-07-29 19:00:00 |
| Consumer fact sheet: Zolpidem (including Stilnox brand) | NPS clarifies issues related to Stilnox, a brand of Zolpidem, including potential side effects, and alternative approaches to sleeping better. | Consumer publication - NPS factsheet | Consumers | 2008-02-01 00:00:00 |
| Zolpidem sleeping tablets | Fact sheet on zolpidem sleeping tablets (including Stilnox brand), with information on minimising side effects and non-drug interventions for insomnia. | Media factsheet | Others | 2008-02-01 00:00:00 |
| Hypnotic hazards of z-drugs immeasurable | It is difficult to know the extent of the use and adverse effects of zolpidem and other z-drugs (zopiclone and zaleplon) because they have never been listed on the Australian Pharmaceutical Benefits Scheme, senior Sleep Disorders Physician Dr Les Olson writes in the latest edition of Australian Prescriber | Media release | Others | 2008-11-26 00:00:00 |
| NPS clarifies issues related to Stilnox, a brand of zolpidem | National Prescribing Service Limited (NPS) is advising consumers concerned about the possible adverse reactions associated with the sleeping medicine Stilnox (zolpidem) to visit their doctor to assess whether they are at risk. | Media release | Others | 2008-02-22 00:00:00 |
| Zolpidem (Stilnox) and insomnia management – NPS info for prescribers and patients | To help prescribers and pharmacists counsel patients concerned about the sleep-related adverse effects associated with zolpidem (Stilnox), the National Prescribing Service Limited (NPS) has today released a position statement on the drug and sleep-related behaviours | Media release | Others | 2008-08-11 00:00:00 |
| NPS Position Statement: Zolpidem and sleep-related behaviours | This NPS Position Statement highlights warnings from the Therapeutic Goods Administration (TGA) about the use of the hypnotic drug zolpidem and its possible association with dangerous sleep-related behaviours | NPS position statement | Health Professionals | 2008-07-01 00:00:00 |
| NPS Position Statement: Zolpidem and sleep-related behaviours | This NPS Position Statement highlights warnings from the Therapeutic Goods Administration (TGA) about the use of the hypnotic drug zolpidem and its possible association with dangerous sleep-related behaviours. | NPS position statement | Health Professionals | 2008-07-01 00:00:00 |
| Stilnox | Consumer information from the manufacturer about the use of Stilnox (zolpidem tartrate). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2008-02-29 00:00 |
| Stilnox CR | Consumer information from the manufacturer about the use of Stilnox CR (zolpidem tartrate). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2008-02-29 00:00 |
| Dormizol | Consumer information from the manufacturer about the use of Dormizol (zolpidem tartrate). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2008-02-29 00:00 |
| GenRx Zolpidem | Consumer information from the manufacturer about the use of GenRx Zolpidem. | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2010-06-09 00:00:00 |
| Somidem | Consumer information from the manufacturer about the use of Somidem (contains the active ingredient zolpidem tartrate). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2009-03-12 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
